Athersys (NASDAQ:ATHX) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Athersys (NASDAQ:ATHX) in a research report sent to investors on Thursday. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Athersys Price Performance

Athersys has a 52 week low of $0.01 and a 52 week high of $1.99. The firm has a market capitalization of $833,000.00, a P/E ratio of 0.00 and a beta of -0.90.

Athersys Company Profile

Athersys, Inc, a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions.